854584-01-3

Basic information

• Product Name: 2(1H)-Quinoxalinone, 6-broMo-3,4-dihydro-
• Synonyms: 2(1H)-Quinoxalinone, 6-broMo-3,4-dihydro-;6-broMo-1,2-dihydroquinoxalin-2-ol;6-Bromo-3,4-dihydroquinoxalin-2(1H)-one;6-BroMo-3,4-dihydro-1H-quinoxalin-2-one
• CAS NO: 854584-01-3
• Molecular Formula: C₈H₇BrN₂O
• Molecular Weight: 227.05798
• Mol File: 854584-01-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.610±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 2(1H)-Quinoxalinone, 6-broMo-3,4-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinoxalinone, 6-broMo-3,4-dihydro-(854584-01-3)
• EPA Substance Registry System: 2(1H)-Quinoxalinone, 6-broMo-3,4-dihydro-(854584-01-3)

Safety Data

• Hazardous Substances Data: 854584-01-3(Hazardous Substances Data)

Usage

General Description

2(1H)-Quinoxalinone, 6-broMo-3,4-dihydro- is a chemical compound belonging to the quinoxalinone family, with a molecular formula of C9H8BrNO. It is commonly used in the synthesis of various pharmaceuticals and organic compounds. It is known for its potent biological activities, including its potential antiviral, anticancer, and antibacterial properties. The 6-broMo-3,4-dihydro- substitution on the quinoxalinone ring structure contributes to its unique chemical and biological properties, making it a valuable compound for research and drug development purposes.

Upstream product

• 1486183-97-4 ethyl 2-(5-brom9-2-nitro-anilino)acetate 
• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 854583-85-0 N-(4-bromo-2-nitrophenyl)-2-chloroacetamide 
• 875-51-4 4-Bromo-2-nitroaniline 
• 854583-92-9 N-(2-amino-4-bromophenyl)-2-chloroacetamide 

Downstream Products

• 305790-79-8 6-bromo-4-methyl-3,4-dihydroquinoxalin-2(1H)-one 
• 55687-34-8 6-bromoquinoxalin-2(1H)-one 
• 55687-02-0 6-bromo-2-chloro-quinoxaline 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS

The present invention provides a compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof has an BET family protein inhibitory action, and is useful as an agent for the prophylaxis or treatment of autoimmune diseases and/or inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis, idiopathic pulmonary fibrosis, psoriasis, atopic dermatitis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, systemic lupus erythematosus etc.), cancer and the like.

Heteroatom insertion into 3,4-dihydro-1 H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase

Aldosterone synthase (CYP11B2) catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone. CYP11B2 is regarded as a new target for several cardiovascular diseases which are associated with chronically elevated aldosterone levels such as hypertension, congestive heart failure and myocardial fibrosis. In this paper, we optimized heterocycle substituted 3,4-dihydropyridin-2(1H)-ones as CYP11B inhibitors by systematic introduction of heteroatoms and by bioisosteric exchange of the lactame moiety by a sultame moiety. The most promising compounds regarding inhibition of human CYP11B2 and selectivity versus human enzymes CYP11B1, CYP17, and CYP19 were tested for inhibition of rat CYP11B2. Thus, we discovered compounds 4 and 9 which show potent inhibition of hCYP11B2 (IC50 1 nM) and the corresponding rat enzyme (4: 64%, 9: 51% inhibition, at 2. 2 μM).

6-PYRIDIN-3-YL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN ALDOSTERONE SYNTHASE CYP11B2

The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl substituted quinolinone derivatives for the treatment of hyperaldosteronism and/or disorders or diseases that are mediated by 11 β-hydroxylase (CYP11 B1 ).